Answers are grounded in this paper and cite their sources.
Review article discusses regenerative strategies, including cell and gene therapies, for Parkinson's disease, highlighting future directions.
Regenerative medicine for Parkinson's disease (PD) is expected to develop dramatically with the advancement of biotechnology as represented by induced pluripotent stem cells. Existing therapeutic strategy for PD consists of medication using L-DOPA, surgery such as deep brain stimulation and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestoration is strongly desired by regenerative medicine. This review article describes the historical development of regenerative medicine for PD, with a focus on fetal nigral cell transplantation and glial cell line-derived neurotrophic factor infusion. Subsequently, the current status of regenerative medicine for PD in terms of cell therapy and gene therapy are reviewed. In the end, the future direction to realize regenerative medicine for PD is discussed.
No takes yet. Share an insight, caveat, or question.
Yasuhara et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: